profit from every $100 of sales.
$0$100
InfuSystem Holdings
$15.08-1.31% today
+44.3% in 1 year
1-year low $7.421-year high $15.28
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay $45.59 for every $1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What InfuSystem Holdings sold, what it kept, and what it did with the cash.
Sales went from $110 million in 2022 to $143 million in 2025, with $6.63 million of profit last year.
SalesProfit
InfuSystem Holdings handed back 70% of the cash it generated last year.
Buybacks $11M
Free cash flow 2025$16M
Bought back its own shares$11M
Paid as dividends–
Cash vs. debt$3M vs. $23M
InfuSystem Holdings vs. similar companies
InfuSystem Holdings grows in the middle of these 5 and is priced in the middle for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| InfuSystem Holdings | 45.6× · Expensive | ||
 ResMed | 22.0× · Fair price | ||
 West Pharmaceutical Services | 58.3× · Expensive | ||
 Hologic | 30.0× · Fair price | ||
 Baxter International | No profit yet |
AI analysis
An AI analyst reads InfuSystem Holdings's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 110 | 126 | 135 | 143 | |
| 61 | 63 | 70 | 80 | |
| 2 | 4 | 7 | 12 | |
| 15 | 17 | 19 | 25 | |
| 0 | 1 | 2 | 7 | |
| 0.00 | 0.04 | 0.11 | 0.31 | |
| 55.1% | 50.2% | 52.2% | 56.0% | |
| 1.5% | 3.2% | 5.1% | 8.3% | |
| 0.0% | 0.7% | 1.7% | 4.6% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 99 | 103 | 104 | 101 |
| Cash | 0 | 0 | 1 | 3 |
| Total debt | 37 | 35 | 28 | 23 |
| Total liabilities | 51 | 51 | 46 | 43 |
| 48 | 52 | 58 | 57 | |
| 22 | 22 | 22 | 21 | |
| 1.4% | 3.6% | 6.3% | 11.7% | |
| 0.0% | 1.7% | 4.1% | 11.6% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 18 | 11 | 20 | 24 | |
| 15 | 11 | 18 | 9 | |
| 2 | 0 | 3 | 16 | |
| Dividends paid | – | – | – | – |
| 7 | 1 | 2 | 11 | |
| 4 | 4 | 4 | 4 |
Valuation
- 45.6×
- 36.3×
- 0.07
- 2.9×
- 2.1×
- 19.2×
- 12.8×
- 5.2%
- 2.2%
- 0.0%
Profitability
- 56.0%
- 8.3%
- 4.6%
- 18.5%
- 10.6%
- 3.3%
- 14.0%
- 8.0%
- 15.8%
- –
Growth
- +9.3%
- +618.7%
- +808.1%
- –
- +0.2%
Financial health
- 0.8×
- 0.39
- 23.1%
- 15.3×
- 2.14
- 1.80
- 1.44
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 26%of 958
Bottom 46%of 888
Bottom 27%of 600
Bottom 44%of 889
Top 22%of 987
What analysts expect
- Average price target
- $15.00
- Range
- $15.00 – $15.00
- 1 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 7, 2026 | 0.05 | 0.04 | +25.0% |
| Feb 24, 2026 | 0.10 | 0.07 | +42.9% |
| Nov 4, 2025 | 0.11 | 0.08 | +37.5% |
| Aug 5, 2025 | 0.12 | 0.03 | +300.0% |
| May 8, 2025 | -0.01 | -0.03 | +66.7% |
| Mar 4, 2025 | 0.04 | 0.08 | −50.0% |
| Nov 7, 2024 | 0.08 | 0.06 | +33.3% |
| Aug 8, 2024 | 0.03 | 0.04 | −18.2% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
50No pass
Benjamin Graham
40No pass
Philip Fisher
37No pass
Peter Lynch
52No pass
Joel Greenblatt
13No pass
Charlie Munger
33No pass
Terry Smith
33No pass
Questions about InfuSystem Holdings
Is InfuSystem Holdings a good stock to buy?
A business with weak numbers, but the price is high. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the InfuSystem Holdings AI analysis
What does InfuSystem Holdings do?
InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Integrated Therapy Services (ITS) and Durable Medical Equipment Services (DME Services). It is in Medical - Instruments & Supplies.
Does InfuSystem Holdings pay a dividend?
No. InfuSystem Holdings does not pay a dividend at the moment; in 2025 it returned $11.0 million to shareholders by buying back its own shares.
Is InfuSystem Holdings stock halal?
Yes. InfuSystem Holdings passes our halal screen: its business is permitted and its debt is 8% of its market value, under the 30% limit. How we check
How has InfuSystem Holdings stock done over the past year?
Up 44.3% over the past twelve months, to $15.08. It traded between $7.42 and $15.28, close to its high.
Who are InfuSystem Holdings's competitors?
The largest listed companies in the same industry are ResMed, West Pharmaceutical Services, Hologic and Baxter International. The peers table on this page compares their profit, growth and price with InfuSystem Holdings's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.